Search Tag: REDUCE-IT!

Cardiology Management

2019 17 Apr

Findings from the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (REDUCE-IT) show that icosapent ethyl, a purified ethyl ester of eicosapentaenoic acid (EPA) reduces the risk of major adverse cardiovascular effects (MACE) by 25%. This included a 20% reduction in death from cardiovascular causes, reductions in other pre-specified...Read more